


## OARRS Guidance - MOUD Clarity

**Updated 9/3/2025**


Effective September 4, 2025, OARRS Patient Reports will include information on patients who may be experiencing medication for opioid use disorder (MOUD) treatment discontinuation. This information is intended to support a more comprehensive assessment by healthcare professionals, which may lead to more timely care coordination efforts.

**IMPORTANT:** For the purposes of this alert, MOUD includes buprenorphine dispensed by pharmacies to treat opioid use disorder as well as naltrexone dispensed by pharmacies. It does **NOT** include methadone, buprenorphine, or naltrexone obtained from an opioid treatment program (OTP).


Beginning September 4, 2025, this new information provided by MOUD Clarity will display on the state indicators tile of the Patient Report when accessing OARRS through both the OARRS PMP AWARxE website and through OARRS integration with electronic health records.



The MOUD Clarity alert is activated when the MOUD medication has not been dispensed by the pharmacy within 8 days of when the next prescription would be expected either because no prescription was issued, or a prescription was issued but not filled. An email will be sent to all providers who have prescribed MOUD to that patient in the last 45 days (see example on next page).



Finally, when the MOUD Clarity alert is activated, it will also display on authorized users' [OARRS AWAReE](#) Dashboards for 45 days.



The Ohio Board of Pharmacy encourages you to familiarize yourself with this feature and explore how it can enhance patient evaluation and care planning. For additional information on MOUD Clarity, please use the following resources:

- [Ohio Specific Frequently Asked Questions](#) (starting on [Page 4](#) of this document)

- [MOUD Clarity](#) help article or the [PMP AWARxE Support Center](#).

Additionally, you may contact the Ohio Board of Pharmacy's OARRS Department at [support@pharmacy.ohio.gov](mailto:support@pharmacy.ohio.gov) with any questions or concerns.

#### **DISCLAIMER**

MOUD Clarity is intended to aid, not replace, medical decision making. None of the information presented in MOUD Clarity should be used as sole justification for providing or not providing care or medications to a patient.

**MOUD Clarity** relies on PDMP data received by Bamboo Health as of the time of generation of the **Patient Report**. As such, Bamboo Health does not warrant that the data relied upon by **MOUD Clarity** is complete, accurate, or error-free. Alerts may appear for patients who do not have gaps in MOUD treatment or may otherwise be limited if the data is unavailable, delayed, or incomplete.

## Frequently Asked Questions

### Q1) What issue is this new feature trying to address?

Poor adherence to medications for opioid use disorder (MOUD) protocols for individuals diagnosed with opioid use disorder (OUD) could result in the relapse and increased risk of both non-fatal and fatal overdose. Despite this risk, healthcare professionals often have limited time with patients and might not be able to obtain a patient's full health history during brief visits. Additionally, missed refill appointments may be a red flag for discontinuation that is often not addressed by healthcare professionals due to resource constraints for tracking missed appointments and outreach.

### Q2) How did the Board determine what criteria to use for this alert?

The criteria were developed from research conducted by Northeastern University (NEU) to better understand the nature and extent of poor adherence to MOUD. NEU interviewed addiction medicine prescribers and patients who have been prescribed buprenorphine to identify the characteristics that are associated with both poor and successful medication adherence. This research has also provided guidance in establishing the criteria used for the MOUD Alert.

The associated alerts and indicators will be triggered for patients who have received at least one buprenorphine or naltrexone prescription dispensed by a pharmacy within the previous 45 days and have not received another buprenorphine or naltrexone prescription within 8 days after the expected exhaustion of medication as calculated by the pharmacy reported "Days' Supply" of the most recent prescription.

**REMINDER:** For the purposes of this alert, MOUD includes buprenorphine dispensed by pharmacies to treat opioid use disorder as well as naltrexone dispensed by pharmacies. It does **NOT** include methadone, buprenorphine, or naltrexone obtained from an opioid treatment program (OTP).

**Q3) Does this alert include MOUD provided by licensed opioid treatment programs?**

No. The alert is only based on MOUD (buprenorphine or naltrexone) dispensed by pharmacies and reported to OARRS. Methadone, buprenorphine, and naltrexone provided by Ohio-licensed OTPs will not be included in this alert. Please be advised that OARRS does alert prescribers and pharmacists of patients who are actively being treated as part of an OTP. This alert is based upon patient consent and may not show up for every patient receiving treatment at an OTP.